|
Deadly effect of arsenic in drinking water measured in massive study 10-year project finds arsenic linked to more than one-fifth of deaths in parts of Bangladesh 06/22/2010 - More than 20 percent of deaths in a study of 12,000 Bangladeshis were attributable to arsenic exposure from contaminated drinking water, new research reports. The large 10-year study is the first to p... http://www.bionity.com/news/e/119230/
Vetter investment will enhance strategic partnership Start of construction for modern center for visual inspection and logistics 06/22/2010 - A groundbreaking ceremony was held for Vetter’s newest facility, Ravensburg Vetter West. Vetter will build a state-of-the-art high bay warehouse for cold-storage and room-temperature goods. Space will... http://www.bionity.com/news/e/119201/
FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients 06/22/2010 - Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chron... http://www.bionity.com/news/e/119177/
Jessica Mann to leave Evolva and join Roche 06/22/2010 - Evolva Holding SA announced that Dr. Jessica Mann will resign as Chief Medical Officer of Evolva as of 31 July 2010 to take up a Senior Development position as Head of Translational Medicine at Hoffm... http://www.bionity.com/news/e/119198/
Second Ohio State cancer drug begins clinical trials testing 06/22/2010 - For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove ... http://www.bionity.com/news/e/119231/
Wild potato germplasm holds key to disease resistance 06/21/2010 - Wild potato germplasm that offers resistance to some major potato diseases has been identified by Agricultural Research Service (ARS) scientists. Geneticists Dennis Halterman and Shelley Jansky pinpoi... http://www.bionity.com/news/e/119093/
Devgen and PT (Persero) Sang Hyang Seri sign memorandum of understanding on the introduction of biotech rice in Indonesia 06/21/2010 - Devgen and PT (Persero) Sang Hyang Seri (SHS) herewith further strengthen their relationship. The companies have already ongoing agreements for R&D, production and distribution of non-transgenic hybri... http://www.bionity.com/news/e/119082/
TcLand Expression appoints personalized medicine pioneer Patrick Terry as Chairman of the Board of Directors 06/21/2010 - TcLand Expression SA announced the appointment of Patrick Terry as Chairman of the company's Board of Directors. Patrick Terry (a Board member since 2009) succeeds TcLand Expression CEO Alain Huriez M... http://www.bionity.com/news/e/119083/
Experts explore emerging evidence linking diabetes and cancer 06/21/2010 - A new consensus statement of experts assembled by the American Diabetes Association and the American Cancer Society reviews emerging evidence that suggests cancer incidence is associated with diabetes... http://www.bionity.com/news/e/119096/
Evotec Earns Milestone in Oncology Programme as Part of its Research Alliance with Boehringer Ingelheim 06/21/2010 - Evotec AG announced that it has achieved a milestone as part of its research alliance with Boehringer Ingelheim and will receive a payment of EUR 2.5 million. The milestone was achieved for the selec... http://www.bionity.com/news/e/119084/
Probiodrug Obtains Additional US Patent for the Inhibition of the Enzyme Glutaminyl Cyclase (QC) to Treat CNS Diseases 06/18/2010 - Probiodrug AG announced that Probiodrug has been granted US patent no. 7,732,162 covering additional subject matters for the company's QC inhibitors by the United States Patent Office. The patent com... http://www.bionity.com/news/e/119062/
RIKEN and SISSA develop new biological analysis methods 06/18/2010 - Researchers in Japan and Italy have developed new methods for biological analysis with dramatically higher sensitivity and detail than earlier techniques, expanding our understanding of RNA and its fu... http://www.bionity.com/news/e/118963/
Minapharm Pharmaceuticals Acquires Majority Stake in ProBioGen Dr. Wieland Wolf Appointed New CEO 06/18/2010 - ProBioGen AG announced that Minapharm Pharmaceuticals, Cairo, has completed the acquisition of 95% of the share capital of ProBioGen, an internationally renowned German cell line development and contr... http://www.bionity.com/news/e/119061/
Abundance of Raw Materials and New Production Units Drive the Bioplastics Market in Brazil and Mexico Given Higher Prices, Consumer Perception Important for Widespread Adoption 06/18/2010 - Both Brazil and Mexico are nascent markets for bioplastics, compared to those in Europe or the U.S. Nevertheless, bioplastics are currently penetrating such segments as food packaging and agricultural... http://www.bionity.com/news/e/119063/
DSM to manufacture C. difficile compound for Novacta Biosystems 06/18/2010 - DSM BioSolutions announced that it has entered into an agreement with Novacta Biosystems Limited for the process development and cGMP production of its C. difficile molecule, a new class of lantibioti... http://www.bionity.com/news/e/119013/
Addex's ADX48621 Effective in Preclinical Parkinson's Disease Studies 06/17/2010 - Allosteric modulation company Addex Pharmaceuticals Ltd presented encouraging data from preclinical studies demonstrating the anti-Parkinson's effects of ADX48621, a novel drug candidate that has comp... http://www.bionity.com/news/e/119009/
SIRS-Lab and Analytik Jena cooperate on Sepsis Diagnostics 06/17/2010 - SIRS-Lab GmbH and Analytik Jena AG will be strengthened by working together in the field of molecular sepsis diagnostics. As part of this cooperation, Analytik Jena subsidiary AJ Innuscreen GmbH will ... http://www.bionity.com/news/e/119005/
InSCREENeX Appoints Henrik L. Luessen as Chief Business Officer 06/17/2010 - InSCREENeX GmbH announced the appointment of Dr. Henrik L. Luessen to the position of Chief Business Officer. He will be responsible for business and strategic development with a particular focus on l... http://www.bionity.com/news/e/118984/
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound Anti-VEGF PRS-050 is first Anticalin tested in humans 06/17/2010 - Pieris AG announced the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the c... http://www.bionity.com/news/e/118985/
Novozymes and Lignol sign deal to make biofuel from wood Partners to develop a commercially viable process for making ethanol from forestry waste 06/17/2010 - Novozymes and Lignol Energy Corporation signed a research and development agreement to make biofuel from wood chips and other forestry residues. The partners aim to develop a process for making biofue... http://www.bionity.com/news/e/118987/
INEOS Bio wins grant for Europe's first Advanced bioethanol from waste plant. INEOS Bio awarded £7.3m grant from One North East and the Department for Energy and Climate Change for construction of Europe’s first advanced bioethanol from waste plant using the INEOS BioEnergy Process Technology 06/16/2010 - INEOS Bio announced that it has received an offer of a £7.3m grant towards £52m construction costs for the first commercial plant in Europe using its advanced BioEnergy Process Technology. The plant, ... http://www.bionity.com/news/e/118958/
OGT Awarded ISO 9001:2008 for its Management Systems Certification highlights commitment to providing high quality products and services 06/16/2010 - Oxford Gene Technology (OGT announced that the management system at its Oxford, UK Headquarters has been certified to BS EN ISO 9001:2008 by the British Standards Institution (BSI. The scope of certif... http://www.bionity.com/news/e/118951/
Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non- Hodgkin's Lymphoma 06/16/2010 - Micromet, Inc. announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL). A... http://www.bionity.com/news/e/118982/
Leukocare appoints VP Business Development Expands team and relocates operations to the IZB in Martinsried/Munich 06/16/2010 - Leukocare AG announced that it has appointed Dr. Wolfram Altenhofen as its new VP Business Development. Dr. Altenhofen previously was responsible for building up sales forces in Europe and India. A... http://www.bionity.com/news/e/118956/
Innovacell Includes First Patients in a Phase IIb Study for Its Cell Therapy Product urocell 06/16/2010 - "First patient in" is the call from the Innsbruck firm, Innovacell Biotechnologie AG, as the first patient was recruited at the MHAT Plovdiv clinic in Bulgaria for the Phase IIb study of the advanced ... http://www.bionity.com/news/e/118983/
|